EUVIMEDEUVIMED entdecken
Crossref

Targeting Ovarian Cancer With Pyrimidine Nucleobase and Nucleoside Analogs: Synthesis, In Vitro Cytotoxic Activity, and Molecular Docking

Hilal Zivali, Arya Akdağ iD, Büşra Demirkan, İrem Durmaz Şahin iD, Meral Tunçbilek iD

Archiv der Pharmazie · 2025

DOI: 10.1002/ardp.70117 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Archiv der Pharmazie, 2025. Verfasst von Hilal Zivali und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Ankara University, Ankara, Turkey. Hauptthemen laut MEDLINE: Ovarian Neoplasms, Antineoplastic Agents, Pyrimidines, Poly(ADP-ribose) Polymerase Inhibitors. Die Arbeit nennt 49 Literaturangaben. Gefördert von: The authors received no specific funding for this study..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Ovarian cancer remains one of the most lethal gynecological malignancies, underscoring the need for novel therapeutic strategies. In this study, a series of pyrimidine‐based nucleobase ( 7–14 ) and nucleoside ( 21–24 ) analogs were synthesized and evaluated for their potential anticancer activity through poly(ADP‐ribose) polymerase (PARP) inhibition. These compounds were tested for in vitro cytotoxicity on ovarian cancer cell lines OVCAR‐3 and KURAMOCHI. Among the synthesized derivatives—namely, 4‐(4‐substituted phenylamino)‐1‐cyclopentyl‐5‐( H /methyl)pyrimidine‐2(1 H )‐ones ( 7–14 ) and 4‐(4‐substituted phenylamino)‐1‐(β‐ d ‐ribofuranosyl)‐5‐methylpyrimidine‐2(1 H )‐ones ( 21–24 )—compound 8 exhibited the most potent cytotoxic activity. It significantly reduced cell viability in OVCAR‐3 (IC 50 = 27.1 ± 4.56 µM) and KURAMOCHI (IC 50 = 46.2 ± 4.87 µM) cells, outperforming the reference PARP inhibitor olaparib (IC 50 = 75.8 ± 6.1 µM for OVCAR‐3, IC 50 = 84.5 ± 11.4 µM for KURAMOCHI). These results suggest that compound 8 is a promising lead candidate for further development as an anticancer agent targeting PARP in ovarian cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ovarian NeoplasmsAntineoplastic AgentsPyrimidinesPoly(ADP-ribose) Polymerase InhibitorsNucleosidesHumansFemaleStructure-Activity RelationshipMolecular Docking SimulationDrug Screening Assays, AntitumorCell Line, TumorMolecular StructureCell SurvivalDose-Response Relationship, DrugCell Proliferation

Stichwörter der Autor:innen

molecular dockingnucleobasenucleosideovarian cancerpyrimidine

Substanzen

Antineoplastic AgentsPyrimidinesPoly(ADP-ribose) Polymerase InhibitorsNucleosides

Autor:innen und Institutionen

  • Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Ankara University, Ankara, Turkey.
  • Department of Pharmaceutical Chemistry, Institute of Health Sciences, Ankara University, Ankara, Turkey.
  • Research, Center for Translational Medicine (KUTTAM), Koç University, İstanbul, Turkey.
  • Koç University Graduate School of Health Sciences, Istanbul, Turkey.
  • Department of Medical Biology, School of Medicine, Koç University, İstanbul, Turkey.

ORCID-Profile: Arya Akdağ, İrem Durmaz Şahin, Meral Tunçbilek

Förderung

  • The authors received no specific funding for this study.

Zitieren

APA

Zivali, H., Akdağ, A., Demirkan, B., Durmaz Şahin, İ., & Tunçbilek, M. (2025). Targeting Ovarian Cancer With Pyrimidine Nucleobase and Nucleoside Analogs: Synthesis, In Vitro Cytotoxic Activity, and Molecular Docking. Archiv der Pharmazie. https://doi.org/10.1002/ardp.70117

Vancouver

Zivali H, Akdağ A, Demirkan B, Durmaz Şahin İ, Tunçbilek M. Targeting Ovarian Cancer With Pyrimidine Nucleobase and Nucleoside Analogs: Synthesis, In Vitro Cytotoxic Activity, and Molecular Docking. Archiv der Pharmazie. 2025. doi:10.1002/ardp.70117

BibTeX
@article{Zivali2025,
  author = {Zivali, Hilal and Akdağ, Arya and Demirkan, Büşra and Durmaz Şahin, İrem and Tunçbilek, Meral},
  title = {Targeting Ovarian Cancer With Pyrimidine Nucleobase and Nucleoside Analogs: Synthesis, In Vitro Cytotoxic Activity, and Molecular Docking},
  journal = {Archiv der Pharmazie},
  year = {2025},
  doi = {10.1002/ardp.70117}
}
Kostenlos starten →